GC 1118A

Drug Profile

GC 1118A

Alternative Names: Anti-EGFR monoclonal antibody - Green Cross; GC 1118; GC1118A

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Green Cross
  • Developer GC Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Colorectal cancer; Gastric cancer

Most Recent Events

  • 30 Apr 2018 Phase-II clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater) in South Korea (IV) (NCT03618667)
  • 02 Apr 2018 Phase-I/II clinical trials in Colorectal cancer (Second-line therapy or greater, Metastatic disease, Recurrent, Combination therapy) in South Korea (IV) (NCT03454620)
  • 02 Apr 2018 Phase-I/II clinical trials in Gastric cancer (Second-line therapy or greater, Combination therapy, Metastatic disease, Recurrent) in South Korea (IV) (NCT03454620)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top